Name | rac-Modipafant |
---|---|
Synonyms | ethyl 4-(2-chlorophenyl)-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyridin-1-yl)phenyl]-5-(pyridin-2-ylcarbamoyl)-1,4-dihydropyridine-3-carboxylate |
Description | (Rac)-Modipafant (UK-74505) is an orally active, selective, long-acting irreversible platelet activating factor receptor (PAFR) antagonist. (Rac)-Modipafant prevents dengue infection[1][2][3]. |
---|---|
Related Catalog | |
In Vivo | (Rac)-Modipafant (UK-74505) (10 mg/kg; p.o.; twice a day until day 10) prevents Severe Dengue Infection[3]. (Rac)-Modipafant exhibits highly selective, time-dependent inhibition of PAF-induced aggregation of rabbit washed platelets (IC50=26.3 and 1.12 nM after 0.25 and 60 min preincubation, respectively)[4]. (Rac)-Modipafant (5-20 mg/kg; p.o.) dose-dependently inhibits the Zymosan -induced articular hyperalgesia[5]. Animal Model: 8- to 10-week-old BALB/c mice (DEN-2 strain infected)[3] Dosage: 10 mg/kg Administration: P.o.; twice a day (started on days 0, 3, 5, or 7) until day 10 Result: Decreased by approximately 50% the lethality associated with DEN-2 infection. Animal Model: Male BALB/C (8- to 10- week-old) wild-type mice[5] Dosage: 5, 10 and 20 mg/kg Administration: P.o. Result: Dose-dependently inhibited the Zymosan -induced articular hyperalgesia. |
References |
Density | 1.34g/cm3 |
---|---|
Molecular Formula | C34H29ClN6O3 |
Molecular Weight | 605.08500 |
Exact Mass | 604.19900 |
PSA | 114.52000 |
LogP | 7.32950 |
Index of Refraction | 1.681 |